BMEA · Biomea Fusion, Inc.

Biomea Fusion’s Q1 2026 financial results reflect a deliberate shift toward operational efficiency: net loss improved by $16.9 million year-over-year, driven by a $13.8 million decline in R&D expenses and a $3.2 million reduction in G&A expenses. The R&D decrease stemmed largely from lower external clinical costs ($3.8M), reduced preclinical spending ($1.9M), and a $4.5 million drop in personnel-related expenses—including stock-based compensation—due to headcount reduction. G&A savings were similarly anchored in personnel cuts and lower corporate expenses. Management attributed this disciplined cost management to sustaining key value drivers while extending cash runway to Q1 2027. Clinically, the Company advanced all major programs: chronic toxicology completion for icovamenib enabled plans for extended dosing beyond 12 weeks; 52-week COVALENT-112 data demonstrated durable C-peptide preservation in early and established T1D, reinforcing menin inhibition as a disease-modifying approach; and two new Phase II T2D trials (COVALENT-211/212) are actively enrolling toward 26-week readouts in Q4 2026. Concurrently, the Phase I GLP-131 trial for BMF-650 is on track for initial 28-day weight loss data in Q2 2026. These developments collectively signal execution against near-term catalysts while preserving capital for upcoming inflection points—particularly the Q4 2026 data readouts, which could materially influence valuation and partnership prospects. No forward guidance on future financials or clinical timelines beyond stated expectations was provided.